首页> 外文OA文献 >The Efficacy of Low Dose Captopril Adjuvant for Natriuresis in Patient with Liver Cirrhosis with Ascites Who Have Received Furosemide and Spironolacton
【2h】

The Efficacy of Low Dose Captopril Adjuvant for Natriuresis in Patient with Liver Cirrhosis with Ascites Who Have Received Furosemide and Spironolacton

机译:小剂量卡托普利佐剂对肝硬化合并呋塞米和螺内酯的腹水患者钠尿的疗效

摘要

Background: The ideal therapy for ascites in liver cirrhosis is a low sodium diet and a combination of furosemide and spironolacton. However, this still sometimes does not produce satisfactory Results, even after increasing the dose of the diuretic. Such failure occurs due to the influence of the Renin Angiotensin Aldosterone (RAA) system. Low doses of ACE inhibitors (captopril) should improve renal blood flow and increase filtration at the glomeruli, thus increasing natriuresis without causing haemodynamic imbalance. Study aim: To discover the natriuretic and diuretic effects of low dose captopril adjuvant in patients with liver cirrhosis who have received furosemide and spironolacton by measuring urinary sodium and 24-hour urine output. Materials and method: This study was conducted on in- and out- patients with liver cirrhosis and Ascites at the Dr. Kariadi Central Public Hospital, Semarang, who met the inclusion and exclusion criteria. The study took place from June 1st, 1997 to March 31st, 1998, and included 40 cases of liver cirrhosis with ascites. Study design: Open comparative randomized clinical trial with permuted blocks. All of the patients received a low fat diet, 40 mg of furosemide, 3x50 mg of spironolacton for 2 weeks, and patients with a urinary sodium level was below 80 mEq/L were randomized into two groups: group A receiving 3 x 6.25 mg of captopril, and group B receiving standard therapy. Results: Variable Pre- treatment Post – treatment p Group A : Urinary sodium level (meq/L) 65.450 ± 16.577 109.950 ± 49.109 0.001 24-hour urine output (cc) 1138.750 ± 480.438 1381.250 ± 394.441 0.004 Group B: Urinary sodium level (meq/L) 68.30 ± 12.85 91.750 ± 64.04 0.103 24-hour urine output (cc) 1390 ± 448.27 1392.50 ± 713.46 0.988 The pre- and post- treatment Results for Group A were significantly different. The pre- and post- treatment Results for Group B were not significantly different. Conclusion: Low dose (3 x 6.25 mg) captopril adjuvant in patients with liver cirrhosis and ascites who have received standard doses of furosemide and spironolacton could increase natriuresis and diuresis without causing haemodynamic imbalance.
机译:背景:肝硬化腹水的理想疗法是低钠饮食以及速尿和螺内酯的组合。但是,即使在增加利尿剂的剂量后,有时仍不能产生令人满意的结果。由于肾素血管紧张素醛固酮(RAA)系统的影响而发生这种故障。低剂量的ACE抑制剂(卡托普利)应改善肾血流量并增加肾小球的过滤,从而增加利尿作用而不会引起血流动力学失衡。研究目的:通过测量尿钠和24小时尿量,发现低剂量卡托普利佐剂对接受速尿和螺内酯的肝硬化患者的利钠和利尿作用。材料和方法:本研究是在三宝垄卡里亚迪中央公立医院符合入选和排除标准的住院和门诊肝硬化和腹水患者中进行的。该研究于1997年6月1日至1998年3月31日进行,包括40例肝硬化腹水患者。研究设计:开放比较性随机临床试验,排列排列。所有患者均接受低脂饮食,40 mg速尿,3x50 mg螺内酯治疗2周,并且尿钠水平低于80 mEq / L的患者随机分为两组:A组接受3 x 6.25 mg卡托普利和B组接受标准治疗。结果:可变的治疗前治疗后p组A:尿钠水平(meq / L)65.450±16.577 109.950±49.109 0.001 24小时尿量(cc)1138.750±480.438 1381.250±394.441 0.004 B组:尿钠水平( meq / L)68.30±12.85 91.750±64.04 0.103 24小时尿量(cc)1390±448.27 1392.50±713.46 0.988 A组的治疗前和治疗后结果显着不同。 B组的治疗前后结果无显着差异。结论:低剂量(3 x 6.25 mg)卡托普利佐剂用于接受标准剂量速尿和螺内酯的肝硬化和腹水患者可增加利尿和利尿作用,而不会引起血流动力学失衡。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号